Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking

Jeffrey J. Goldberger*, Rod Passman

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations

Abstract

The risk of sudden death is highest early after myocardial infarction (MI) and progressively declines over the ensuing 6 to 12 months. Nevertheless, several randomized clinical trials have failed to show a survival benefit for implantable cardioverter-defibrillators when implanted early after MI in high-risk patients. The etiology of this acute MI-sudden cardiac death paradox is unclear, but may be related to the changing nature of the substrate over the several month period after acute MI. Further investigation is needed to delineate the actual causes of death in the early post-MI period and which interventions can be implemented to reduce the increased rate of sudden death that is observed.

Original languageEnglish (US)
Pages (from-to)2001-2005
Number of pages5
JournalJournal of the American College of Cardiology
Volume54
Issue number22
DOIs
StatePublished - Nov 24 2009

Keywords

  • implantable defibrillator
  • myocardial infarction
  • sudden death

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Implantable Cardioverter-Defibrillator Therapy After Acute Myocardial Infarction. The Results Are Not Shocking'. Together they form a unique fingerprint.

Cite this